Have a new diagnosis of type 1 diabetes within 100 days prior to starting study intervention
Have at least one diabetes-related autoantibody found at screening
Show signs of remaining beta-cell function
* stimulated (peak or 90 min) C-peptide ≥0.2 nmol/L (0.6 ng/mL) at screening
Weigh at least 8 kilograms (kg) (18 pounds) at screening
You may not be if
Have any other type of diabetes including gestational
Have uncontrolled high blood pressure
Have had a heart attack, heart disease, stroke, or heart failure
Have a history or high risk of venous thromboembolism, lymphoproliferative disease or malignancy
Have a current or recent clinically serious medical condition or infection
Clareo Health | A Study of Baricitinib (LY3009104) to Preserve Beta Cell Function in Children and Adults Newly Diagnosed With Type 1 Diabetes (BARICADE-PRESERVE)
